New drug trial aims to tackle severe obesity
NCT ID NCT07000955
Summary
This study is testing a new drug called IBI362 to see if it is safe and how it affects the body in people with moderate to severe obesity. It involves 98 Chinese adults and compares the new drug to a placebo (inactive substance) and another weight-loss medication. The main goals are to check for side effects and measure how the drug is processed in the body, while also looking at changes in weight and body fat.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OBESITY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
The Affiliated Hospital of Nanjing University Medical School
Nanjing, Jiangsu, 210003, China
Conditions
Explore the condition pages connected to this study.